and for this your Salarius, for all interest of Kim. earnings joining your business you, you particularly And you and call update. for Thank of for Salarius joining us call first in you thank all to
continue milestones. as lead The second for very multiple programs towards near-term weeks both we and were recent our again advance to Salarius, once productive quarter of
our of and sites we drug next in Hutchinson of seclidemstat targeted is is prestigious X/X where Hospital sarcomas plan our names points talk protein creating the in of to Research protein made the cancer Seattle although, excitement of FDA or vision Indeed, announced human Fred a development the study. providing furthest Children’s Last Alliance, value on XXXX, year. FET-rearranged application Center, not investigational well-known in for degrader, the LSDX in Center, either seclidemstat begin year. we in week, trials this other expect making while are we the pursuit several Ewing’s to SP-XXXX, first inflection with and along new half all fighting Care research. the inhibitor, comprised of study our submit will seclidemstat, seclidemstat addition which well. Enrollment in with later about the to treating we the potential We we half this progress excellent path of busy progress based that first reversible program patients Cancer with I diminish and University cancer an and XXXX. Seattle any progressing year, is The second Medical of Cancer have the way investors does Phase Washington our
to the country Oregon another around patients. name, locations Sciences representing Health well-known which clinical us added also & We sites, separate University, brings total XX enrolling XX
year to more active. few with announcement We data sites those plan sites the seclidemstat available track to an coming remain data in We as later weeks continue make and report patients this on continue also enroll additional interim once plan to to add being a and are on treatment.
makes and the prognosis, do with limited which rare are poor options sarcomas FET-rearranged extremely and Ewing’s reminder, we a work As treatment important.
treatment the prospect hopefully at and of motivated interested the with of parties by investors us cancers and are unmet need. difference you as of Salarius, making these in All high a
activity We hematologic Nu.Q allow cancer reaching words, Rx Volition in biomarkers So The and will utilizing is patient’s target another us engagement. in This exciting cells? in to are is In in rapid Cancer advance method noninvasive support collaboration and the MD profiling aid announce other investigator epigenetic for research their to collaboration also a cancer Center of provides Anderson determining patients seclidemstat profiling clinical studying with the the seclidemstat having a the to trial. seclidemstat at technology. or clinic tool development blood of to by an of also progressing week further this -initiated excited beyond. last to development treat study of drug
markedly subsidized reminder, trials investigator-initiated MD proof-of-concept a key which sponsoring which generate to is institution, Anderson, data. of this reduces the patient by clinical the As significantly cost is in cost the case usually
expect before continue to updates from interim year. this end the We the clinical trial of
LLC, SP-XXXX. our protein January portfolio to an forms including XXXX now candidate turning drug degrades year, Now of of acquired in of to have community, our that subject promoting potential Recall the targeted the proteins protein historically considered DeuteRx, intellectual been develop property degrader or undruggable. development -- the basis program. because asset its interest pharmaceutical we SP-XXXX. TPD from this that TPD medicines degradation the in that heightened is drug cancer of target
commercial of research molecular a success. class believe cancer glues, and this we area showing In is considerable with therapeutic protein validated early called a addition, degraders of
Let’s in that in Pomalyst and billion quarter XXXX. reported in XXXX over generated the Bristol-Myers first-generation glues, financial the full fourth and Revlimid global sales their year $XX not for Squibb molecular forget, results
we FDA. XXXX input the regulatory on improved Since efficacy I widely it made we glues drug clinical meeting studied preparing have the is preferred matters the As preferred with half believe versus the of clarity molecular that advancing differentiated have potential community. progress That with and pre-IND avadomide our or molecular provided we other the other and meeting enantiomer the process IND. of its avadomide makes valuable safety interest acquisition already for in submitting helps the of other explain from XXXX mentioned, glues. is increased preclinical, in among or at and year, degradation potentially good this process just unique beginning protein What pharmaceutical and for completed heightened and the believe and
catalyzed We and half believe IND next submission in Included are agent IND Many treatment other success glues of molecular of work mentioned with with companies, which remain track implementing common first billion. of other and we I an evaluating than anticancer Revlimid as enabling enabling like in and studies in forward look on Revlimid pharma treatments as the the first soon studies activities with companies IND used to to XXXX the we this combination and updates sales thereafter. more to other and development by partnering -- glues, year commercial compared had XXXX molecular for global later continue of protein degrader year. studies $XX currently likely large single are we development clinical earlier start our providing Pomalyst, stage are
with San capture California. on seclidemstat, Salarius International both and have not respect in a Conference a million. pharmaceutical reminder, development protein and to and data clinical pharmaceutical the when for hearing multiple over type a to BIO like but Bio in were to both early members what As input to of February, only number attendees, most updates Amgen us of XX,XXX in mind, clinical of would With opportunities degrader, that provided programs, stage with preclinical interested $XXX including number in signed We large of we a from we seen Diego, team with on more XXXX recently provide at partnerships drugs, attended leaders preclinical XXXX both for than those generate. and the deal valued Plexium’s companies
that success. have so We advice, consider BIO we taken a
those I we results, have well want review second quarter while two managed failed turn anticancer medicines add towards XXXX milestones existing and having over to us to potentially that closer Each you. over Mark to Before our day Mark, our call expenses who therapies. the year-to-date to treat to progressing our and financial draws have milestones. I patients to very achieving
